Common Specifications for Class D In Vitro Diagnostic Medical Devices
On 5 of July of 2022, the European Commission published the implementing Regulation (EU) 2022/1107 of 4 July 2022 laying down common specifications for certain class D in vitro diagnostic medical devices in accordance with Regulation (EU) 2017/746.

For certain class D in vitro diagnostic medical devices, there are no harmonised standards to respond to some requirements of Annex I of Regulation (EU) 2017/746. However, there is a need to address public health concerns as they can pose significant risks for public health and patient safety. Therefore, it is appropriate to adopt common specifications for those devices in respect of those requirements.

The common technical specifications under the Directive 98/79/EC were set out in Commission Decision 2002/364/EC. Once the Regulation (EU) 2017/746 replaced the Directive 98/79/EC, some of those common technical specifications have to be updated to reflect the current state of the art.

Entry into force and date of application

Regulation (EU) 2022/1107:

  • Enters into force in 25 July 2022
  • Applies from 25 July 2024

Transitional provisions

To ensure a continuous high level of safety and performance of devices, as a transitional measure, it is presumed that devices in conformity with Decision 2002/364/EC are in conformity with the requirements for certain performance characteristics set out in Annex I of Regulation (EU) 2017/746 until 25 July 2024.

Devices that are not in conformity with the common technical specifications set out in Decision 2002/364/EC should adopt solutions to ensure an equivalent level of safety and performance.

Devices that are in conformity with the common specifications set out in Regulation (EU) 2022/1107 are presumed to be in conformity with the performance requirements referred in Annex I to Regulation (EU) 2017/746.

Which requirements of Annex I of Regulation (EU) 2017/746 are covered by the common specifications?

Regulation (EU) 2022/1107 lays down common specifications for certain class D in vitro diagnostic medical devices in respect to the following performance requirements set out in Annex I to Regulation (EU) 2017/746:

  • Section 9.1, points (a) and (b)
  • Section 9.3
  • Section 9.4, point (a)

List of annexes of Regulation (EU) 2022/1107

  • Annex I – general common specifications for devices covered by Annexes II to XIII
  • Annex II – common specifications for devices intended for detection of blood group antigens in the ABO, Rh, Kell, Duffy and Kidd blood group systems.
  • Annex III – common specifications for devices intended for detection or quantification of markers of human immunodeficiency virus (HIV) infection.
  • Annex IV – common specifications for devices intended for detection or quantification of markers of human T-cell lymphotropic virus (HTLV) infection.
  • Annex V – common specifications for devices intended for detection or quantification of markers of hepatitis C virus (HCV) infection.
  • Annex VI – common specifications for devices intended for detection or quantification of markers of hepatitis B virus (HBV) infection.
  • Annex VII – common specifications for devices intended for detection or quantification of markers of hepatitis D virus (HDV) infection.
  • Annex VIII – common specifications for devices intended for detection of markers of variant Creutzfeldt-Jakob disease (vCJD).
  • Annex IX – common specifications for devices intended for detection or quantification of markers of cytomegalovirus (CMV) infection.
  • Annex X – common specifications for devices intended for detection or quantification of markers of Epstein-Barr virus infection (EBV).
  • Annex XI – common specifications for devices intended for detection of markers of Treponema pallidum infection.
  • Annex XII – common specifications for devices intended for detection or quantification of markers of Trypanosoma cruzi infection.
  • Annex XIII – common specifications for devices intended for detection or quantification of markers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

further
reading

parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
medical devices

EUDAMED – harmonized practices and alternative solutions for IVDR until the database is fully functional

EUDAMED is one of the key aspects of the new rules on in vitro diagnostic medical devices – Regulation (EU) 2017/746. However, it is only expected to achieve full functionality by the second quarter of 2024. Until then, how is the information submitted and/or exchanged between manufacturers, notified bodies and competent authorities?

Read More »
medical devices

EUDAMED – update on timelines

EUDAMED is one of the key aspects of the new rules on medical devices (Regulation (EU) 2017/745) and in vitro diagnostic medical devices (Regulation (EU) 2017/746), and it is expected to achieve full functionality by the second quarter of 2024.

Read More »
cosmetic products

UK OPSS call for data on six cosmetic ingredients

On 14 July 2022, the Office for Product Safety and Standards (OPSS – the UK regulator for cosmetic products) issued a call for data on the safety of the following six cosmetic ingredients to investigate any suspected endocrine disrupting properties. 

Read More »
cosmetic products

European Commission Recommendation on the Definition of Nanomaterial

Nanomaterials are increasingly used in cosmetics and personal care products. They are similar to other chemicals/substances, but with specific risks associated to their use. The European Commission has published a new Recommendation to clarify the definition of ‘nanomaterial’. This definition may serve different policy, legislative and research purposes when addressing materials or issues concerning products of nanotechnologies.

Read More »